Abiomed anuncia primeiro paciente cadastrado no estudo de viabilidade IMEST DTU
05 mai 2017 14h00 HE
|
Abiomed
DANVERS, Massachusetts, May 05, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), provedora líder de tecnologias inovadoras de suporte cardíaco, anunciou hoje o cadastro do primeiro...
Abiomed 宣佈STEMI DTU可行性研究 已招募到首位患者
05 mai 2017 14h00 HE
|
Abiomed
美國麻塞諸塞州丹佛斯市, May 06, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc.（納斯達克代碼：ABMD）是一家領先的突破性心臟支支援術提供商，今天宣佈美國食品藥品監管局（FDA）批准的一項前瞻性可行性研究已招募到首位患者。這項研究名為「STEMI從門到卸荷（DTU）」，是對急性心肌梗死患者使用Impella...
Abiomed Mengumumkan Pasien Pertama yang Mengikuti Studi Kelayakan STEMI DTU
05 mai 2017 14h00 HE
|
Abiomed
DANVERS, Mass., May 06, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), penyedia teknologi terobosan dukungan jantung terkemuka, hari ini mengumumkan pasien pertama yang mengikuti studi...
Abiomed、STEMI DTU実現可能性研究における最初の患者の組み入れを発表
05 mai 2017 14h00 HE
|
Abiomed
マサチューセッツ州ダンヴァース, May 06, 2017 (GLOBE NEWSWIRE) -- 画期的な心臓サポートテクノロジーのリーディング･プロバイダー、Abiomed, Inc.（NASDAQ:ABMD） は本日、米国食品医薬品局（FDA）から承認を得た前向き実現可能性研究、「急性心筋梗塞におけるImpella...
Abiomed Mengumumkan Pesakit Pertama yang Mendaftar dalam Kajian Kemungkinan STEMI DTU
05 mai 2017 14h00 HE
|
Abiomed
DANVERS, Mass, May 06, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD), pembekal terkemuka bagi kejayaan teknologi sokongan hati, hari ini mengumumkan pendaftaran pesakit pertama dalam Food...
Abiomed 宣布STEMI DTU可行性研究 已招募到第一位患者
05 mai 2017 14h00 HE
|
Abiomed
国马萨诸塞州丹佛斯市, May 06, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc.（纳斯达克代码：ABMD）是一家领先的突破性心脏支持技术提供商，今天宣布美国食品药品监管局（FDA）批准的一项前瞻性可行性研究已招募到第一位患者。这项研究名为“STEMI从门到卸荷（DTU）”，是对急性心肌梗死患者使用Impella...
Abiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study
04 mai 2017 07h01 HE
|
Abiomed
DANVERS, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announced today the enrollment of the first patient in...
Abiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year
04 mai 2017 07h00 HE
|
Abiomed
DANVERS, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2017 revenue of...
Abiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification
13 avr. 2017 08h00 HE
|
Abiomed
DANVERS, Mass., April 13, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, May 4, 2017, the Company will release financial results for the fourth quarter of fiscal...
Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts
30 mars 2017 12h26 HE
|
Abiomed
DANVERS, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Massachusetts Governor Charlie Baker today joined Abiomed – a leading provider of breakthrough heart support and recovery technologies – for the...